Greenphire Releases New Visual Analytics Features for eClinicalGPS
Greenphire announced it has released new visual analytics functionality for its eClinicalGPS technology
Greenphire, a provider of payment technologies for the clinical trials industry, announced it has released new visual analytics functionality for its eClinicalGPS technology which aims to give clients the tools aggregate strategic data for more effective trial forecasting, planning, tracking, and quantitative assessment.
By linking key cost drivers like subject enrollment and site-level clinical activity to contract and other financial data, clients are able to have a clear picture of their finances in relation to the trial, so they can make more effective business decisions, in real-time, that ensure a trial is completed on-time and on-budget.
For further information on Greenphire and its solutions please email: [email protected] or visit www.greenphire.com.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
